|
Ulcerative Colitis
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
In the pediatric cohort the associations of TNFSF15, NKX2-3 with CD, and PTGER4, NKX2-3, ZNF365, IFNG, PSMG1 with UC, were confirmed.
|
21818367 |
2011 |
|
Ulcerative Colitis
|
0.310 |
Biomarker
|
disease |
CTD_human |
Genome-wide association identifies multiple ulcerative colitis susceptibility loci.
|
20228799 |
2010 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Characterizing rare and low-frequency height-associated variants in the Japanese population.
|
31562340 |
2019 |
|
Migraine Disorders
|
0.050 |
Biomarker
|
group |
BEFREE |
Our results demonstrate that the repetitive electrical stimulation model can simulate the allodynia during the migraine chronification, and PACAP plays a role in the pathogenesis of migraine potentially via PAC1 receptor.
|
30799680 |
2019 |
|
Migraine Disorders
|
0.050 |
Biomarker
|
group |
BEFREE |
The selective increase in pituitary adenylate cyclase-activating polypeptide-related receptors suggests that the PAC1 receptor pathway is a novel target for the treatment of migraine.
|
28776455 |
2018 |
|
Migraine Disorders
|
0.050 |
Biomarker
|
group |
BEFREE |
In the present review we summarize the protective effects of PACAP in ischemia, especially in neuronal ischemic injuries, and discuss possible points to consider when developing strategies in migraine therapy interfering with the PACAP/PAC1 receptor system.
|
29500688 |
2018 |
|
Migraine Disorders
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The expression of PAC1 receptors and the high potency of PACAP to induce MMA vasodilation are consistent with their potential roles in the etiology of migraine.
|
22766684 |
2012 |
|
Migraine Disorders
|
0.050 |
Biomarker
|
group |
BEFREE |
We pharmacologically characterized pituitary adenylate cyclase-activating polypeptides (PACAPs), vasoactive intestinal peptide (VIP) and the VPAC(1), VPAC(2) and PAC(1) receptors in human meningeal (for their role in migraine) and coronary (for potential side effects) arteries.
|
20974589 |
2011 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Pac 1 binds to PI4K2A and disrupts the PKR/PI4K2A-associated lysosome complex, contributing to destabilization of cancer cell lysosomes and triggering cell death.
|
31554935 |
2020 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Based on these findings a decrease or lack of the PAC1 receptor/PACAP signalling might have an influence on tumour growth and/or differentiation.
|
31788045 |
2019 |
|
Sudden infant death syndrome
|
0.040 |
Biomarker
|
disease |
BEFREE |
These findings suggest that PAC1 plays the principal role in mediating the cardiorespiratory effects of PACAP in response to hypoxic stress during neonatal development and that defective PACAP signaling via PAC1 may contribute to the pathogenesis of SIDS.
|
30758978 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
When given to mice bearing subcutaneous or orthotopic xenograft, PAC-1 and WF-210 inhibited the tumor growth and tumor angiogenesis.
|
29269017 |
2018 |
|
Schizophrenia
|
0.040 |
Biomarker
|
disease |
BEFREE |
The neuroprotective effect via PAC-1 activation suggests a potentially novel pharmacological target for the treatment of schizophrenia, via neurogenesis normalization.
|
28125634 |
2017 |
|
Sudden infant death syndrome
|
0.040 |
Biomarker
|
disease |
BEFREE |
SIDS compared to non-SIDS had higher PACAP in the MBDR (p<0.05) and lower PAC1 in the medulla arcuate nucleus (p<0.001).
|
28392470 |
2017 |
|
Sudden infant death syndrome
|
0.040 |
Biomarker
|
disease |
BEFREE |
Pituitary adenylate cyclase activating polypeptide (PACAP) and its cognate receptor 1 (PAC1), have been implicated in the pathophysiology of the Sudden Infant Death Syndrome (SIDS).
|
28506824 |
2017 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Finally, PAC-1 remains potent against vemurafenib-resistant A375VR cells in cell culture and synergizes with vemurafenib to exert antitumor effects on A375VR cell growth in vivo Collectively, our data suggest that inhibition of MAPK signaling combined with concurrent procaspase-3 activation is an effective strategy to enhance the antitumor activity of vemurafenib and mitigate the development of resistance.Mol Cancer Ther; 15(8); 1859-69.©2016 AACR.
|
27297867 |
2016 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Therefore, the aim of the present study was to investigate expression of PACAP and its PAC1 receptor in human thyroid papillary carcinoma, the most common endocrine malignant tumor.
|
27566169 |
2016 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Both IL-2 vectors exerted significant tumor growth delay; however, attempts to further enhance antitumor activity of the IL-2 vectors by combining with the proapoptotic drug procaspase activating compound 1 (PAC1) were unsuccessful.
|
27151235 |
2016 |
|
Schizophrenia
|
0.040 |
Biomarker
|
disease |
BEFREE |
Mice lacking the gene encoding pituitary adenylate cyclase-activating polypeptide (PACAP) or its specific receptor, PAC1, show abnormal behaviors related to schizophrenia.
|
27383213 |
2016 |
|
Sudden infant death syndrome
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Overall, this study does not support a strong association between variants in the PAC1 gene and SIDS; however, a number of potential associations between race-specific variants and SIDS were identified that warrant targeted investigations in future studies.
|
23981011 |
2013 |
|
Schizophrenia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
In addition, an association between SNPs of the PACAP or PAC1 genes and schizophrenia has been reported.
|
19958095 |
2009 |
|
Schizophrenia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Here, we provide evidence that genetic variants of the genes encoding PACAP and its receptor, PAC1, are associated with schizophrenia.
|
17387318 |
2007 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
A weaker immunostaining of PAC1 receptors in normal tissue and a strong density of the three PACAP/VIP receptor subclasses in cancer tissue may be related to differential expression patterns during breast tumor progression but more samples need to be studied to validate this hypothesis.
|
16019382 |
2005 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
The expression analysis of the DSCR2 gene in different human tumour derived cell lines indicates that the gene is expressed in all proliferating cell lines tested.
|
10872820 |
2000 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Pac 1 binds to PI4K2A and disrupts the PKR/PI4K2A-associated lysosome complex, contributing to destabilization of cancer cell lysosomes and triggering cell death.
|
31554935 |
2020 |